Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2020

Open Access 01-12-2020 | Computed Tomography | Case report

A case of insulin-like growth factor 2-producing gastrointestinal stromal tumor with severe hypoglycemia

Authors: Haruka Yamasaki, Ayako Itawaki, Miwa Morita, Hitomi Miyake, Masahiro Yamamoto, Hiroki Sonoyama, Sayuri Tanaka, Masakazu Notsu, Mika Yamauchi, Yusuke Fujii, Noriyoshi Ishikawa, Izumi Fukuda, Shunji Ishihara, Keizo Kanasaki

Published in: BMC Endocrine Disorders | Issue 1/2020

Login to get access

Abstract

Background

Non-islet cell tumor hypoglycemia (NICTH) is a rare paraneoplastic syndrome that secretes incompletely processed high molecular weight insulin growth factor 2 (big-IGF2), which results in stimulation of the insulin receptor and subsequently induces hypoglycemia. Gastrointestinal stromal tumor (GIST) is a common intestinal mesenchymal neoplasm of the gastrointestinal tract. The most frequent site of GIST is the stomach; NICTH induced by IGF2-producing stomach GISTs is rare.

Case presentation

An 84-year-old man was admitted to the hospital due to impaired consciousness (JCS II-10) in the morning. At the time of admission, his serum glucose was 44 mg/dL; his consciousness was restored with 20 ml of 50% glucose. To avoid hypoglycemia, a continuous intravenous infusion of glucose as well as dietary intervention was required. At the time of hypoglycemia, the levels of insulin and C-peptide were suppressed. Additionally, IGF1 levels were below the normal range. Abdominal computed tomography revealed that he had a large lobulated mass (116 × 70 × 72 mm) around the gastric corpus. Pathological analysis of biopsy specimens identified disarray of spindle cells and positivity for c-kit as well as strong positivity for DOG-1. Further analysis revealed high levels of Ki-67 (Mib-1 index: 15.5%) and mitotic index (7/50HPF); the tumor was diagnosed as high-risk GIST, and complete surgical resection was performed. Hypoglycemia resolved immediately after tumor resection. The resected tumor specimen was positive for IGF2 staining, and big-IGF2 (11–18 kDa) was detected in preoperative serum and tumor samples; the patient was diagnosed with NICTH due to an IGF2-producing tumor.

Conclusions

NICTH is rare in GIST of the stomach; however, the large GIST could produce big-IGF2 and subsequently cause severe hypoglycemia, requiring prompt evaluation and complete tumor resection.
Literature
1.
go back to reference Daughaday WH, Emanuele MA, Brooks MH, Barbato AL, Kapadia M, Rotwein P. Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med. 1988;319(22):1434–40.PubMedCrossRef Daughaday WH, Emanuele MA, Brooks MH, Barbato AL, Kapadia M, Rotwein P. Synthesis and secretion of insulin-like growth factor II by a leiomyosarcoma with associated hypoglycemia. N Engl J Med. 1988;319(22):1434–40.PubMedCrossRef
2.
go back to reference Bodnar TW, Acevedo MJ, Pietropaolo M. Management of non-islet-cell tumor hypoglycemia: a clinical review. J Clin Endocrinol Metab. 2014;99(3):713–22.PubMedCrossRef Bodnar TW, Acevedo MJ, Pietropaolo M. Management of non-islet-cell tumor hypoglycemia: a clinical review. J Clin Endocrinol Metab. 2014;99(3):713–22.PubMedCrossRef
3.
go back to reference Rikhof B, de Jong S, Suurmeijer AJ, Meijer C, van der Graaf WT. The insulin-like growth factor system and sarcomas. J Pathol. 2009;217(4):469–82.PubMedCrossRef Rikhof B, de Jong S, Suurmeijer AJ, Meijer C, van der Graaf WT. The insulin-like growth factor system and sarcomas. J Pathol. 2009;217(4):469–82.PubMedCrossRef
4.
go back to reference Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577–80.PubMedCrossRef Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577–80.PubMedCrossRef
5.
go back to reference Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708–10.PubMedCrossRef Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708–10.PubMedCrossRef
6.
go back to reference Chan KH, Chan CW, Chow WH, Kwan WK, Kong CK, Mak KF, Leung MY, Lau LK. Gastrointestinal stromal tumors in a cohort of Chinese patients in Hong Kong. World J Gastroenterol. 2006;12(14):2223–8.PubMedPubMedCentralCrossRef Chan KH, Chan CW, Chow WH, Kwan WK, Kong CK, Mak KF, Leung MY, Lau LK. Gastrointestinal stromal tumors in a cohort of Chinese patients in Hong Kong. World J Gastroenterol. 2006;12(14):2223–8.PubMedPubMedCentralCrossRef
7.
go back to reference Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, Jeong JS, Cho MY, Jin SY, Choi JS, et al. Gastrointestinal stromal tumors in Koreans: it's incidence and the clinical, pathologic and immunohistochemical findings. J Korean Med Sci. 2005;20(6):977–84.PubMedPubMedCentralCrossRef Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, Jeong JS, Cho MY, Jin SY, Choi JS, et al. Gastrointestinal stromal tumors in Koreans: it's incidence and the clinical, pathologic and immunohistochemical findings. J Korean Med Sci. 2005;20(6):977–84.PubMedPubMedCentralCrossRef
8.
go back to reference DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231(1):51–8.PubMedPubMedCentralCrossRef DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231(1):51–8.PubMedPubMedCentralCrossRef
9.
go back to reference Burvin R, LeRoith D, Harel H, Zloczower M, Marbach M, Karnieli E. The effect of acute insulin-like growth factor-II administration on glucose metabolism in the rat. Growth Hormon IGF Res. 1998;8(3):205–10.CrossRef Burvin R, LeRoith D, Harel H, Zloczower M, Marbach M, Karnieli E. The effect of acute insulin-like growth factor-II administration on glucose metabolism in the rat. Growth Hormon IGF Res. 1998;8(3):205–10.CrossRef
10.
go back to reference de Groot JW, Rikhof B, van Doorn J, Bilo HJ, Alleman MA, Honkoop AH, van der Graaf WT. Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. Endocr Relat Cancer. 2007;14(4):979–93.PubMedCrossRef de Groot JW, Rikhof B, van Doorn J, Bilo HJ, Alleman MA, Honkoop AH, van der Graaf WT. Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. Endocr Relat Cancer. 2007;14(4):979–93.PubMedCrossRef
11.
go back to reference Fukuda I, Hizuka N, Takano K, Asakawa-Yasumoto K, Shizume K, Demura H. Characterization of insulin-like growth factor II (IGF-II) and IGF binding proteins in patients with non-islet-cell tumor hypoglycemia. Endocr J. 1993;40(1):111–9.PubMedCrossRef Fukuda I, Hizuka N, Takano K, Asakawa-Yasumoto K, Shizume K, Demura H. Characterization of insulin-like growth factor II (IGF-II) and IGF binding proteins in patients with non-islet-cell tumor hypoglycemia. Endocr J. 1993;40(1):111–9.PubMedCrossRef
12.
go back to reference Rikhof B, van Doorn J, Suurmeijer AJ, Rautenberg MW, Groenen PJ, Verdijk MA, Jager PL, de Jong S, Gietema JA, van der Graaf WT. Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestinal stromal tumour. Ann Oncol. 2009;20(9):1582–8.PubMedCrossRef Rikhof B, van Doorn J, Suurmeijer AJ, Rautenberg MW, Groenen PJ, Verdijk MA, Jager PL, de Jong S, Gietema JA, van der Graaf WT. Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestinal stromal tumour. Ann Oncol. 2009;20(9):1582–8.PubMedCrossRef
13.
go back to reference Fukuda I, Hizuka N, Ishikawa Y, Yasumoto K, Murakami Y, Sata A, Morita J, Kurimoto M, Okubo Y, Takano K. Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. Growth Hormon IGF Res. 2006;16(4):211–6.CrossRef Fukuda I, Hizuka N, Ishikawa Y, Yasumoto K, Murakami Y, Sata A, Morita J, Kurimoto M, Okubo Y, Takano K. Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. Growth Hormon IGF Res. 2006;16(4):211–6.CrossRef
14.
go back to reference Hizuka N, Fukuda I, Takano K, Okubo Y, Asakawa-Yasumoto K, Demura H. Serum insulin-like growth factor II in 44 patients with non-islet cell tumor hypoglycemia. Endocr J. 1998;45(Suppl):S61–5.PubMedCrossRef Hizuka N, Fukuda I, Takano K, Okubo Y, Asakawa-Yasumoto K, Demura H. Serum insulin-like growth factor II in 44 patients with non-islet cell tumor hypoglycemia. Endocr J. 1998;45(Suppl):S61–5.PubMedCrossRef
15.
go back to reference Yakar S, Rosen CJ, Bouxsein ML, Sun H, Mejia W, Kawashima Y, Wu Y, Emerton K, Williams V, Jepsen K, et al. Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism. FASEB J. 2009;23(3):709–19.PubMedPubMedCentralCrossRef Yakar S, Rosen CJ, Bouxsein ML, Sun H, Mejia W, Kawashima Y, Wu Y, Emerton K, Williams V, Jepsen K, et al. Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism. FASEB J. 2009;23(3):709–19.PubMedPubMedCentralCrossRef
16.
go back to reference Rikhof B, van der Graaf WT, Suurmeijer AJ, van Doorn J, Meersma GJ, Groenen PJ, Schuuring EM, Meijer C, de Jong S. 'Big'-insulin-like growth factor-II signaling is an autocrine survival pathway in gastrointestinal stromal tumors. Am J Pathol. 2012;181(1):303–12.PubMedCrossRef Rikhof B, van der Graaf WT, Suurmeijer AJ, van Doorn J, Meersma GJ, Groenen PJ, Schuuring EM, Meijer C, de Jong S. 'Big'-insulin-like growth factor-II signaling is an autocrine survival pathway in gastrointestinal stromal tumors. Am J Pathol. 2012;181(1):303–12.PubMedCrossRef
Metadata
Title
A case of insulin-like growth factor 2-producing gastrointestinal stromal tumor with severe hypoglycemia
Authors
Haruka Yamasaki
Ayako Itawaki
Miwa Morita
Hitomi Miyake
Masahiro Yamamoto
Hiroki Sonoyama
Sayuri Tanaka
Masakazu Notsu
Mika Yamauchi
Yusuke Fujii
Noriyoshi Ishikawa
Izumi Fukuda
Shunji Ishihara
Keizo Kanasaki
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2020
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-020-0529-2

Other articles of this Issue 1/2020

BMC Endocrine Disorders 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine